Perioperative ischaemic evaluation trial

The effect of perioperative metoprolol on cardiac morbidity and mortality in patients presenting for non-cardiac surgery

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000308695

Acronym

POISE

Enrollment

8351

Registered

2005-09-06

Start date

2003-01-31

Completion date

2008-07-28

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Patients with or at risk of ischaemic heart disease, who are having moderate or high risk non-cardiac surgery will be randomized to receive metoprolol CR or placebo for 30 days perioperatively. Outcomes include cardiac morbidity and mortality and safety endpoints.

Interventions

Metoprolol CR 200 mg daily for 30 days.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Prevention

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

45 Years to No maximum

Healthy volunteers

Inclusion criteria

With or at risk of ischaemic heart disease. Having moderatie or high risk non-cardiac surgery.

Exclusion criteria

Bradycardia or heart block, bronchospasm, recent CABG surgery, beta-blockers or verapamil.

Outcome results